BRAF and neoplasm: We also find that NGFRhi tumor cells are cross-resistant to BRAF (+MEK) inhibition, thereby corroborating other recent (single cell) approaches13,25,38–40 and extending previous RNA profiles suggesting co-evolution of MAPKi resistance and CD8 T cell exhaustion41.